|
|
TLR-7 andTLR-8 Agonist |
|
Vaxjo ID |
392 |
|
Vaccine Adjuvant Name |
TLR-7 andTLR-8 Agonist |
|
Alternative Names |
TLR-7 and TLR-8 agonists are sometimes referred to as TLR7/8a. |
|
Adjuvant VO ID |
VO_0005674
|
|
Description |
TLR-7 and TLR-8 agonists are small molecules that mimic the action of viral RNA, activating these Toll-like receptors to stimulate the immune system, particularly enhancing CD8 T cell responses. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
Small molecule Toll-like receptor-7 and -8 agonists (TLR-7/8a),imiquimod and resiquimod |
|
Structure |
they often include imidazoquinoline derivatives, such as Imiquimod and Resiquimod. |
|
Appearance |
The appearance of TLR-7 and TLR-8 agonists is typically as a white to off-white powder |
|
Function |
we covalently attached TLR-7/8a to polymers of varying composition, chain architecture and hydrodynamic behavior (∼300 nm submicrometer particles, ∼10 nm micelles and ∼4 nm flexible random coils) and evaluated how these parameters of polymer-TLR-7/8a conjugates impact adjuvant activity in vivo. |
|
Safety |
TLR-7 and TLR-8 agonists have been shown to have a favorable safety profile in clinical applications, but they can cause side effects such as local inflammation and flu-like symptoms when administered systemically. |
| References |
Lynn et al., 2019: Lynn GM, Chytil P, Francica JR, Lagová A, Kueberuwa G, Ishizuka AS, Zaidi N, Ramirez-Valdez RA, Blobel NJ, Baharom F, Leal J, Wang AQ, Gerner MY, Etrych T, Ulbrich K, Seymour LW, Seder RA, Laga R. Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. Biomacromolecules. 2019; 20(2); 854-870. [PubMed: 30608149].
|
|
